We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$280M
AUM Growth
+$4.87M
Cap. Flow
-$17.4M
Cap. Flow %
-6.19%
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$5.21M
2
ANSS
Ansys
ANSS
+$4.33M
3
JNPR
Juniper Networks
JNPR
+$4.19M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$2.49M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.36M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$12.3M
2
IMVT icon
Immunovant
IMVT
+$5.11M
3
IMGN
Immunogen Inc
IMGN
+$4.29M
4
SPLK
Splunk Inc
SPLK
+$4.2M
5
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.78%
2 Technology 11.84%
3 Consumer Discretionary 7.8%
4 Industrials 6.17%
5 Financials 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
51
Cogent Biosciences
COGT
$6.61B
$1.89M 0.67%
281,093
– –
GOOG icon
52
Alphabet (Google) Class C
GOOG
$4.19T
$1.88M 0.67%
12,336
-800
-6% -$115K
GE icon
53
GE Aerospace
GE
$382B
$1.77M 0.63%
15,814
-5,513
-26% -$650K
KNSA icon
54
Kiniksa Pharmaceuticals
KNSA
$6.07B
$1.75M 0.62%
88,688
– –
BBIO icon
55
BridgeBio Pharma
BBIO
$16.4B
$1.75M 0.62%
56,562
+11,990
+27% +$408K
JD icon
56
JD.com
JD
$43.1B
$1.71M 0.61%
62,465
+12,200
+24% +$299K
TVTX icon
57
Travere Therapeutics
TVTX
$5.68B
$1.69M 0.6%
219,416
– –
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.68M 0.6%
24,337
+14,792
+155% +$1.02M
AUTL
59
Autolus Therapeutics
AUTL
$620M
$1.67M 0.59%
+261,324
New +$1.63M
VZ icon
60
Verizon
VZ
$196B
$1.64M 0.59%
+39,100
New +$1.58M
GPCR icon
61
Structure Therapeutics
GPCR
$3.71B
$1.6M 0.57%
37,444
-37,388
-50% -$1.58M
MU icon
62
Micron Technology
MU
$981B
$1.58M 0.56%
13,400
-4,300
-24% -$389K
TMUS icon
63
T-Mobile US
TMUS
$192B
$1.55M 0.55%
+9,500
New +$1.55M
RIG icon
64
Transocean
RIG
$6.49B
$1.54M 0.55%
245,925
+51,900
+27% +$283K
PFSI icon
65
PennyMac Financial
PFSI
$3.98B
$1.5M 0.53%
16,437
-1,500
-8% -$131K
TDW icon
66
Tidewater
TDW
$4.54B
$1.41M 0.5%
+15,300
New +$1.14M
PTC icon
67
PTC
PTC
$16.3B
$1.39M 0.5%
7,381
-2,000
-21% -$360K
CPT icon
68
Camden Property Trust
CPT
$10.9B
$1.39M 0.49%
+14,100
New +$1.36M
PM icon
69
Philip Morris
PM
$290B
$1.38M 0.49%
15,100
+3,800
+34% +$350K
EQR icon
70
Equity Residential
EQR
$24.4B
$1.38M 0.49%
+21,900
New +$1.33M
TDG icon
71
TransDigm Group
TDG
$68.7B
$1.35M 0.48%
+1,100
New +$1.24M
WDC icon
72
Western Digital
WDC
$151B
$1.35M 0.48%
26,195
-8,335
-24% -$365K
MA icon
73
Mastercard
MA
$492B
$1.23M 0.44%
2,547
-3,500
-58% -$1.6M
VTRS icon
74
Viatris
VTRS
$18.7B
$1.23M 0.44%
+102,600
New +$1.24M
TRML
75
DELISTED
Tourmaline Bio
TRML
$1.21M 0.43%
+53,052
New +$1.87M
1 2
3
4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2024 Portfolio in Review

As of Q1 2024, HighVista Strategies held 166 positions worth $280M, up 1.8% from $276M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $17.4M in Q1 2024, closing 35 positions and reducing 35 holdings. Its most notable exit was Immunovant, an estimated $5.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Apogee Therapeutics worth $7.93M.

  • HighVista Strategies's largest Q1 2024 buy was Apogee Therapeutics: 119,403 shares worth $7.93M.
  • HighVista Strategies added most to argenx in Q1 2024, an estimated $2.2M increase.
  • HighVista Strategies's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $12.3M.
  • HighVista Strategies fully exited Immunovant in Q1 2024, selling an estimated $5.11M.
  • HighVista Strategies's ten largest holdings make up 29% of its $280M portfolio in Q1 2024.
  • HighVista Strategies opened 40 new positions and closed 35 in Q1 2024.
  • HighVista Strategies's portfolio value rose 1.8% quarter-over-quarter to $280M.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.